tradingkey.logo

ENDRA Life Sciences Inc

NDRA
View Detailed Chart

4.790USD

-0.010-0.21%
Close 09/19, 16:00ETQuotes delayed by 15 min
3.60MMarket Cap
LossP/E TTM

ENDRA Life Sciences Inc

4.790

-0.010-0.21%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.21%

5 Days

+1.05%

1 Month

+3.23%

6 Months

+21.36%

Year to Date

-23.48%

1 Year

-35.23%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
202 / 506
Overall Ranking
326 / 4720
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Buy
Current Rating
46.000
Target Price
+858.33%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Overvalued
The company’s latest PE is 0.01, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 22.09K shares, increasing 36.66% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 116.00 shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Ticker SymbolNDRA
CompanyENDRA Life Sciences Inc
CEOMr. Alexander Y. Tokman
Websitehttps://www.endrainc.com/
KeyAI